Richard M. Neve

14.1k total citations · 2 hit papers
53 papers, 4.7k citations indexed

About

Richard M. Neve is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Richard M. Neve has authored 53 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 25 papers in Oncology and 8 papers in Immunology. Recurrent topics in Richard M. Neve's work include HER2/EGFR in Cancer Research (9 papers), Cancer Cells and Metastasis (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Richard M. Neve is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Cells and Metastasis (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Richard M. Neve collaborates with scholars based in United States, Switzerland and Denmark. Richard M. Neve's co-authors include Joe W. Gray, Nancy E. Hynes, Heidi A. Lane, Eva Lin, Jeff Settleman, Genee Y. Lee, Paul T. Spellman, J.M. Daly, Katrin Lorenz and Ole W. Petersen and has published in prestigious journals such as Nature, Science and SHILAP Revista de lepidopterología.

In The Last Decade

Richard M. Neve

53 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Jing Peng, Eva Lin et al. profile →
The morphologies of breast cancer cell lines in three-dimensional assays correlate with \ntheir profiles of gene expression

2008 809 citations Paraic A. Kenny, Genee Y. Lee et al. eScholarship (California Digital Library) profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard M. Neve United States	29	2.8k	2.3k	761	651	570	53	4.7k
Paraic A. Kenny United States	31	2.6k 0.9×	2.1k 0.9×	900 1.2×	854 1.3×	934 1.6×	85	5.2k
Julia Wulfkuhle United States	36	4.1k 1.5×	1.2k 0.5×	791 1.0×	412 0.6×	778 1.4×	81	5.8k
Rebecca S. Cook United States	37	2.7k 1.0×	2.1k 0.9×	954 1.3×	297 0.5×	392 0.7×	73	4.9k
Martin Pruschy Switzerland	36	2.3k 0.8×	1.2k 0.5×	687 0.9×	461 0.7×	354 0.6×	108	4.3k
Johanna Lahdenranta United States	23	2.0k 0.7×	1.4k 0.6×	618 0.8×	295 0.5×	239 0.4×	51	3.6k
Katia Manova‐Todorova United States	27	3.9k 1.4×	2.8k 1.2×	1.2k 1.6×	811 1.2×	633 1.1×	48	6.8k
Alana L. Welm United States	41	4.0k 1.4×	2.4k 1.1×	1.8k 2.4×	494 0.8×	486 0.9×	97	6.5k
Sara Piccirillo Italy	23	2.8k 1.0×	1.8k 0.8×	1.8k 2.3×	319 0.5×	371 0.7×	48	5.0k
Andrew R. Reynolds United Kingdom	31	2.8k 1.0×	1.2k 0.5×	1.2k 1.5×	402 0.6×	296 0.5×	36	4.2k
Paul Yaswen United States	44	3.7k 1.3×	2.3k 1.0×	1.1k 1.5×	759 1.2×	359 0.6×	85	6.2k

Countries citing papers authored by Richard M. Neve

Since Specialization

Citations

This map shows the geographic impact of Richard M. Neve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard M. Neve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard M. Neve more than expected).

Fields of papers citing papers by Richard M. Neve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard M. Neve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard M. Neve. The network helps show where Richard M. Neve may publish in the future.

Co-authorship network of co-authors of Richard M. Neve

This figure shows the co-authorship network connecting the top 25 collaborators of Richard M. Neve. A scholar is included among the top collaborators of Richard M. Neve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard M. Neve. Richard M. Neve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cioffi, Alexander G., Yi Lin, Michael B. Shaghafi, et al.. (2025). Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation. Structure. 33(12). 2020–2028.e7. 1 indexed citations

Wang, Yan, Allison W. Roberts, Philamer Calses, et al.. (2024). Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC. Cancer Research. 84(6_Supplement). 5949–5949. 1 indexed citations

Paroni, Gabriela, Marco Bolis, Adriana Zanetti, et al.. (2018). HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Oncogene. 38(15). 2675–2689. 21 indexed citations

Yin, Yiyuan, Stevan Djakovic, Scot A. Marsters, et al.. (2015). Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Molecular Cancer Therapeutics. 14(10). 2270–2278. 6 indexed citations

Wilson, Catherine, Xiaofen Ye, Eva Lin, et al.. (2014). AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs. Cancer Research. 74(20). 5878–5890. 116 indexed citations

Lee, Genee Y., Peter M. Haverty, Li Li, et al.. (2014). Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes. Cancer Research. 74(11). 3114–3126. 125 indexed citations

Hill, Steven M., Richard M. Neve, Nora Bayani, et al.. (2012). Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology. BMC Bioinformatics. 13(1). 22 indexed citations

Salaita, Khalid, Pradeep M. Nair, Rebecca S. Petit, et al.. (2010). Restriction of Receptor Movement Alters Cellular Response: Physical Force Sensing by EphA2. Science. 327(5971). 1380–1385. 277 indexed citations

Agarwal, Roshan, Simen Myhre, Mark Carey, et al.. (2009). Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research. 15(11). 3654–3662. 111 indexed citations

10.

Neve, Richard M., et al.. (2009). A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. SHILAP Revista de lepidopterología. 26 indexed citations

11.

Park, John W., Richard M. Neve, János Szöllõsi, & Christopher C. Benz. (2008). Unraveling the Biologic and Clinical Complexities of HER2. Clinical Breast Cancer. 8(5). 392–401. 78 indexed citations

12.

Kenny, Paraic A., Genee Y. Lee, Connie A. Myers, et al.. (2008). The morphologies of breast cancer cell lines in three-dimensional assays correlate with \ntheir profiles of gene expression. eScholarship (California Digital Library). 809 indexed citations breakdown →

13.

Neve, Richard M., Bauke Ylstra, Chuan-Hsiung Chang, Donna G. Albertson, & Christopher C. Benz. (2002). ErbB2 Activation of ESX gene expression. Oncogene. 21(24). 3934–3938. 34 indexed citations

14.

Neve, Richard M., Heidi A. Lane, & Nancy E. Hynes. (2001). The role of overexpressed HER2 in transformation. Annals of Oncology. 12. S9–S13. 138 indexed citations

15.

Neve, Richard M., Ulrik B. Nielsen, Dmitri B. Kirpotin, et al.. (2001). Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function. Biochemical and Biophysical Research Communications. 280(1). 274–279. 51 indexed citations

16.

Neve, Richard M., Hedwig Sutterlüty, Nick Pullen, et al.. (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 19(13). 1647–1656. 127 indexed citations

17.

Lane, Heidi A., Iwan Beuvink, Andréa Barretto Motoyama, et al.. (2000). ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 ^Kip1 -Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency. Molecular and Cellular Biology. 20(9). 3210–3223. 253 indexed citations

18.

Croxford, J. Ludovic, Kostas A. Triantaphyllopoulos, Richard M. Neve, et al.. (2000). Gene Therapy for Chronic Relapsing Experimental Allergic Encephalomyelitis Using Cells Expressing a Novel Soluble p75 Dimeric TNF Receptor. The Journal of Immunology. 164(5). 2776–2781. 35 indexed citations

19.

Daly, J.M., et al.. (1999). NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene. 18(23). 3440–3451. 83 indexed citations

20.

Neve, Richard M.. (1969). Neve's The city and country purchaser and builder's dictionary. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact